Singapore markets close in 23 minutes

Lexeo Therapeutics, Inc. (LXEO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
15.00-0.46 (-2.98%)
At close: 04:00PM EDT
15.00 0.00 (0.00%)
After hours: 04:11PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 494.18M
Enterprise value 310.36M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.78
Enterprise value/revenue 416.34
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 349.25%
S&P500 52-week change 326.94%
52-week high 322.33
52-week low 39.00
50-day moving average 313.66
200-day moving average 314.08

Share statistics

Avg vol (3-month) 3133.87k
Avg vol (10-day) 3135.18k
Shares outstanding 532.95M
Implied shares outstanding 632.95M
Float 819.4M
% held by insiders 14.61%
% held by institutions 187.83%
Shares short (15 May 2024) 4684.36k
Short ratio (15 May 2024) 45.4
Short % of float (15 May 2024) 42.33%
Short % of shares outstanding (15 May 2024) 42.08%
Shares short (prior month 15 Apr 2024) 4836.43k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)-54.44%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -71.91M
Net income avi to common (ttm)-69.42M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)195.06M
Total cash per share (mrq)5.92
Total debt (mrq)11.24M
Total debt/equity (mrq)6.14%
Current ratio (mrq)9.16
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-55.99M
Levered free cash flow (ttm)N/A